Biotech Tracker
MilestoneH2 2026a window, not a day

REC-7735 PI3Ka H1047R inhibitor Phase 1/2 start in solid tumors

REC-7735 PI3Ka H1047R inhibitor Phase 1/2 start in solid tumors, expected in the second half of 2026 (no exact date yet). A company milestone for Recursion (REC-7735 for PI3Ka H1047R-mutant solid tumors): a step in the program rather than a decision or a data readout.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsCompany milestone
Company
Recursion Pharmaceuticals, Inc. RXRX
Drug
REC-7735
For
PI3Ka H1047R-mutant solid tumors
Stage
Phase 1/2 · an early study that checks safety and takes a first look at effect
When
H2 2026 · the company gave a window, not a day; the calendar never invents one
Source note
Q2 2026 results PR (Aug 5, 2026): IND for AI-designed REC-7735 cleared; Phase 1/2 trial in select solid tumors expected to start in the second half of 2026.
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
Recursion Pharmaceuticals, Inc.
RXRX
7 upcoming · 1 past catalysts
More from RXRX
MilestoneRXRXRecursionH2 2026

REC-4881 FDA registrational-path update in FAP, expected in the second half of 2026 (no exact date yet). A company milestone for Recursion (REC-4881 (MEK1/2 inhibitor) for familial adenomatous polyposis): a step in the program rather than a decision or a data readout.

More details
Entry
REC-4881 FDA registrational-path update in FAP · Company milestone
Drug
REC-4881 (MEK1/2 inhibitor)
For
familial adenomatous polyposis
Stage
Phase 2 · the stage that tests whether the drug actually works
When
H2 2026 · the company gave a window, not a day
Source note
"Discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26."
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsRXRXRecursionH2 2026

Recursion expects to report results from its Phase 1 study of REC-1245 (RBM39 degrader) for biomarker-enriched solid tumors and lymphoma in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details
Entry
REC-1245 Phase 1 dose-escalation data · Clinical trial results (readout / topline data)
Drug
REC-1245 (RBM39 degrader)
For
biomarker-enriched solid tumors and lymphoma
Stage
Phase 1 · an early safety study in a small group of people
When
H2 2026 · the company gave a window, not a day
Source note
"Additional Phase 1 dose escalation data expected in 2H26."
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceRXRXRecursionNov 2, 2026

Recursion presents data on REC-4881 (MEK1/2 inhibitor) for familial adenomatous polyposis at a medical meeting on Nov 2, 2026. New numbers at a conference can move the stock as much as a formal announcement.

More details
Entry
REC-4881 TUPELO FAP data in Presidential Plenary at CGA-IGC (Nov 2) · Data presented at a medical meeting
Drug
REC-4881 (MEK1/2 inhibitor)
For
familial adenomatous polyposis
Stage
Phase 2 · the stage that tests whether the drug actually works
When
Nov 2, 2026
Source note
more precise date for existing RXRX|conference|2026-11 item. Q2 2026 PR says additional TUPELO Phase 2 safety/efficacy data contextualized with real-world data will be presented at CGA-IGC Annual Meeting, Presidential Plenary I, Nov 2, 2026. FDA registrational-path update still guided for 2H26.
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsRXRXRecursionH1 2027

Recursion expects to report results from its Phase 1 study of REC-617 (CDK7 inhibitor) for advanced solid tumors in the first half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details
Entry
REC-617 Phase 1 combination safety/PK data · Clinical trial results (readout / topline data)
Drug
REC-617 (CDK7 inhibitor)
For
advanced solid tumors
Stage
Phase 1 · an early safety study in a small group of people
When
H1 2027 · the company gave a window, not a day
Source note
"Early Phase 1 safety and PK combination data expected in 1H27."
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsRXRXRecursionH1 2027

Recursion expects to report results from its Phase 1 study of REC-3565 (MALT1 inhibitor) for B-cell malignancies in the first half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details
Entry
REC-3565 Phase 1 monotherapy safety/PK data · Clinical trial results (readout / topline data)
Drug
REC-3565 (MALT1 inhibitor)
For
B-cell malignancies
Stage
Phase 1 · an early safety study in a small group of people
When
H1 2027 · the company gave a window, not a day
Source note
"Early Phase 1 safety and PK monotherapy data expected in 1H27."
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page